Metraipolis › archive › dc_2d11a75bd2f4
A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets — Europe PMC PMID:41499692
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41499692
- DOI
- 10.17305/bb.2026.13832
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T01:22:38.829Z
- SHA-256 of the archived text
73eb4ba4bea7a896d823072a78b48823858c3d0df7a5d116b1ae11a939e9672c- Stable URL of this page
https://metraipolis.com/documento/dc_2d11a75bd2f4
How to cite
A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets — Europe PMC PMID:41499692 — Europe PMC (en), https://europepmc.org/article/MED/41499692 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d11a75bd2f4 (Metraipolis archive dc_2d11a75bd2f4, sha256 73eb4ba4bea7a896d823072a78b48823858c3d0df7a5d116b1ae11a939e9672c)
BibTeX
@misc{dc2d11a75bd2f4,
title = {A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets — Europe PMC PMID:41499692},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41499692},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d11a75bd2f4; sha256 73eb4ba4bea7a896d823072a78b48823858c3d0df7a5d116b1ae11a939e9672c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41499692. Agents can read the archived copy with the MCP tool read_document.